Showing results (601-610 of 622) with videos related to
Sort By:
Pageof 63
Nature Communications|December 21, 2017
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancerDavid Liu, Philip Abbosh, Daniel Keliher, et al.European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.Cancer|April 20, 2017
Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT studyJohn L Gore, Marguerite du Plessis, María Santiago-Jiménez, et al.European Urology|August 5, 2015
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerElizabeth R Plimack, Roland L Dunbrack, Timothy A Brennan, et al.European Urology|July 20, 2025
Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE TrialArvin K George, Ranko Miocinovic, Amit R Patel, et al.Cancers|September 23, 2022
On-Clamp vs. Off-Clamp Robot-Assisted Partial Nephrectomy for cT2 Renal Tumors: Retrospective Propensity-Score-Matched Multicenter Outcome AnalysisAldo Brassetti, Giovanni E Cacciamani, Andrea Mari, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 VaccineRebecca M Shulman, David S Weinberg, Eric A Ross, et al.Neurology|December 8, 2006
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe diseaseP S Kishnani, D Corzo, M Nicolino, et al.Plos One|July 15, 2014
Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studiesJudith S Brand, Maroeska M Rovers, Bu B Yeap, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 14, 2018
CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC studyX Zhang, J Zhou, D-D Zhu, et al.Pageof 63